Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Autobahn Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: https://autobahntx.com
Year Founded: 2017
Status: Private
BioCentury | Jul 25, 2024
Finance
Venture Report: Third Arc’s $165M series A; Brenig heads for clinic with $65M round
Plus: Flagship-backed Abiologics launches; and rounds for GRO, Autobahn and Rona
BioCentury | Sep 8, 2022
Product Development
Sept. 8 Quick Takes: Detailed APOLLO-B data lift Alnylam shares
Plus Autobahn heads for treatment-resistant depression with $32M round and updates on Amylyx, Reata, Integral Molecular and more
BioCentury | Oct 13, 2021
Management Tracks
Harler joins IGM as president of autoimmunity and inflammation business
Plus: Precigen, Transition Bio, Shoreline, Syros, Twist, Vor and more
BioCentury | Sep 28, 2021
Product Development
The TREM2 pipeline: Date Byte
It’s early days for the target, but the therapies directed at the innate immune receptor has begun to reflect its potential
BioCentury | Aug 21, 2021
Targets & Mechanisms
Next-generation multiple sclerosis therapies look beyond B cells
Early-stage approaches aim for more precise immune suppression, remyelination
BioCentury | Aug 13, 2021
Translation in Brief
AAV COVID-19 vaccine provides durable protection in monkeys
Plus mAb-based contraception, metabolites for autism and more
BioCentury | May 13, 2021
Product Development
May 12 Quick Takes: Biogen-TMS in stroke deal; plus Minerva, Autobahn-Astellas, Emergent, Magenta, Fosun-BioNTech
Biogen Inc. (NASDAQ:BIIB) is exercising an option to acquire a next-generation thrombolytic agent from TMS Co. Ltd. The move comes after the Japanese company showed TMS-007 reopened blood vessels and
BioCentury | Jul 16, 2020
Management Tracks
NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more
BioCentury | Jun 10, 2020
Emerging Company Profile
Autobahn: fine-tuning thyroid agonism to remyelinate axons
Arch-incubated remyelination play Autobahn launches with $76M series B
Items per page:
1 - 9 of 9